Advances in Ultrasonography (US) technology allow confident characterization of not only benign cysts but also benign and malignant solid masses.
According to Regina J. Hooley, MD, Leslie M. Scoutt, MD, and Liane E. Philpotts, Md from the Department of Diagnostic Radiology at Yale University School of Medicine, having knowledge of current and emerging US technology, along with meticulous scanning techniques is imperative for image optimization and diagnosis.
The ability to synthesize breast US findings with multiple imaging modalities and clinical information is also necessary to ensure the best patient care.
The full report is available in the September issue of Radiology.
In a separate study, findings were that BI-RADS 3 breast lesions had a lower cancer rate when using ultrasound, since more biopsies must be performed, most of which turn out to be negative.
“Supplemental ultrasound screening increases cancer detection beyond mammography alone, but may also result in an increased number of additional test,” says lead research Richard G. Barr, MD, PhD, and professor of radiology at the Northeast Ohio Medical University in Youngstown, Ohio.
“BI-RADS 3 lesions are common on screening ultrasound and often lead to unnecessary biopsies and additional imaging, causing substantial cost and anxiety for patients,” said Barr.